Stockscreener 앱 받기
0.2484
4.57%
-0.0119
시간 외 거래:
.40
0.1516
+61.03%
전일 마감가:
$0.2603
열려 있는:
$0.2622
하루 거래량:
35.24M
Relative Volume:
8.59
시가총액:
$1.38M
수익:
-
순이익/손실:
$-12.91M
주가수익비율:
-0.00263
EPS:
-94.5617
순현금흐름:
$-12.02M
1주 성능:
-54.35%
1개월 성능:
-31.53%
6개월 성능:
-97.96%
1년 성능:
-99.33%
1일 변동 폭
$0.2404
$0.276
1주일 범위
$0.2362
$0.50
52주 변동 폭
$0.2362
$42.60
Silexion Therapeutics Corp Stock (SLXN) Company Profile
명칭
Silexion Therapeutics Corp
전화
972-8-6286005
주소
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.2484 | 1.45M | 0 | -12.91M | -12.02M | -94.56 |
VRTX
Vertex Pharmaceuticals Inc
|
527.67 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
197.28 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
752.25 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
972.25 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
201.74 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Silexion Therapeutics Corp 주식(SLXN)의 최신 뉴스
Form PRE 14A SILEXION THERAPEUTICS CORP For: 26 September By Investing.com - Investing.com India
Price to sales forward of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView
Silexion Therapeutics Notified of Nasdaq Bid Price Deficiency, Trading Continues Unaffected - Kalkine Media
Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice - TipRanks
Silexion Therapeutics Corp (SLXNW) Stock Price, News, Quote & History - Yahoo Finance
Why Is the Market Watching Silexion Therapeutics (SLXN)? - kalkinemedia.com
Biotech Pre-Market Movers: TNON, AEON Surge; COO, CDT Slide - RTTNews
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewswire
SLXN Q2 2026 Earnings: Loss Per Share of -$5.17 Misses Estimates by 139.09% as Company Remains Pre-RevenueNew Analyst Coverage - dars.gov.et
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN) - TipRanks
Silexion (SLXNW) Range: Finishes Nearly Flat at $0.01 in Latest Trading; Next Test - dars.gov.et
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal - The Globe and Mail
Silexion Therapeutics Received Notice of Delisting - TradingView
Top Silexion Therapeutics CorpWarrant (SLXNW) Competitors 2026 - MarketBeat
Silexion Therapeutics Executes Reverse Share Split Amid Strain - The Globe and Mail
Silexion Therapeutics Closes Public Offering and Strengthens Equity - The Globe and Mail
Silexion Therapeutics (SLXN) seeks huge share boost and reverse split to stay on Nasdaq - Stock Titan
Silexion Q2 EPS $(5.17) misses $(2.12) estimate; loss widens - scanx.trade
Silexion Therapeutics Raises $35 Million in August Public Offering - Minichart
Silexion Therapeutics Corp 2Q 2026: Net loss $3.55M, EPS $(12.41) — 10-Q Summary - TradingView
Silexion Initiates Phase 2/3 Pancreatic Cancer Trial on July 29 - Minichart
Silexion Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Moomoo
Silexion Therapeutics reports Q2 2026: $3.6M Q2 net loss, $2.2M cash at June 30 - TradingView
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Press Release: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Silexion Completes 1-for-10 Reverse Share Split - Minichart
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Nigeria
Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants - Stock Titan
Silexion Therapeutics Corp SEC Filing (Aug 12, 2026) - Stock Titan
Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell - marketscreener.com
Silexion Therapeutics prices $2.5M public offering at $0.65 By Investing.com - Investing.com India
Silexion prices $2.5M offering to fund KRAS cancer trial - Dealroom
Silexion Therapeutics prices $2.5M public offering at $0.65 - Investing.com
Silexion Intends to Use Offering Proceeds for Pancreatic Trial - Stock Titan
Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants - Quiver Quantitative
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire
SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls 31%Earnings Revision Upgrade - dars.gov.et
SLXN Q1 2026 Earnings: Narrower Loss Beats Estimates, Yet Shares Tumble 29%GAAP Earnings Report - dars.gov.et
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - TipRanks
Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - Benzinga
Immunotherapy's Biggest Blind Spot Is A $7 Billion Market. Silexion May Have A Way In (NASDAQ: SLXN) - Menafn
Form 8K Silexion Therapeutics Corp For: 10 August By Investing.com - Investing.com South Africa
Silexion Updates SIL204 Clinical and Regulatory Roadmap - tipranks.com
Silexion Therapeutics (SLXN US): Synthetic Expert Call Transcript (10 Aug 2026) - Smartkarma
Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - Bitget
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Hold Rating - 富途牛牛
IPO Databook: Silexion Therapeutics (SLXN US)Aug 2026 - Smartkarma
Silexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock Titan
Silexion Therapeutics Warrant (SLXNW) Holds Flat at $0.02 as Trading Range CompressesAdvance Decline Line - careplusvn.com
Silexion unveils key SIL204 KRAS preclinical findings - TipRanks
Silexion Therapeutics Corp (SLXN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.27%
자본화:
|
볼륨(24시간):